873 results on '"Mitsudomi, T"'
Search Results
2. Consensus for HER2 alterations testing in non-small-cell lung cancer
3. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
4. OA15.06 Differences in Pathologic Assessment by MPR Calculation Methods for Multiple Slides of Tumor Bed in SQUAT Trial (WJOG12119L)
5. P1.08-05 On-Target Acquired Resistance to Mobocertinib and Strategy to Overcome It - In Vitro Study Using EGFR Ex20 Insertion Models
6. P1.11-01 Utility of ctDNA Monitoring during Surveillance in Surgically Resected NSCLC Patients
7. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
8. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
9. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
10. 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
11. Nivolumab (NIVO) + doublet de chimiothérapie à base de sels de platine (chimio) versus chimio, en traitement néoadjuvant du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) : corrélation entre survie sans évènement (EFS) et régression pathologique dans l’étude CheckMate 816
12. 124P Phase II study of neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable stage IIIA-B N2 non-small cell lung cancer: SQUAT trial (WJOG 12119L)
13. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth
14. 932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
15. EP08.01-005 A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL
16. EP08.02-085 In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI
17. 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study
18. EP08.02-146 Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation
19. Corrigendum to ‘Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer’
20. S-1 as an option for second-line treatment of NSCLC. Is the ‘East Side Story’ applicable in the West?
21. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
22. Role of ctDNA in the Management of Patients with Resected Lung Cancer
23. International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials
24. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting
25. Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
26. Nivolumab (N) + doublet de chimiothérapie à base de sels de platine (CT) vs CT comme traitement néoadjuvant (Tt néoadj) du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) dans l’essai de phase 3 CheckMate 816 (CM 816)
27. Résultats chirurgicaux de l’essai de phase 3 CheckMate 816 (CM 816) : Nivolumab (N) + doublet de chimiothérapie à base de sels de platine (CT) vs CT comme traitement néo-adjuvant du cancer bronchique non à petites cellules (CBNPC) résécable
28. P04.01 Presence of Ground Glass Opacity Component is True Determinant of Prognosis in Clinical Stage I Non-Small Cell Lung Cancer
29. PL02.09 International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials
30. P68.12 Inter-Tumor Heterogeneity of CD44 Expression in Non-Small Cell Lung Cancers / EGFR Mutated Lung Adenocarcinomas
31. Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC): 134O_PR
32. Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results: LBA2_PR
33. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations
34. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer
35. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
36. Molecular Pathogenesis of Lung Cancer : Mutations in Dominant and Recessive Oncogenes, and the Expression of Opioid and Nicotine Receptors in the Pathogenesis of Lung Cancer
37. 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial
38. LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial
39. LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
40. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer
41. P86.05 In Vitro Validation Study for HER2 Mutations Identified in Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
42. P76.71 RYK Confers Drug Tolerance to Osimertinib in Lung Cancer Cells with EGFR Mutations
43. ES28.01 Biology of KRAS Targeting Agents
44. Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach
45. Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women
46. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese
47. Latest innovations in NSCLC management
48. Testing for COVID-19 in lung cancer patients
49. P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
50. P2.17-41 Treatment Outcomes of Pulmonary Resection in NSCLC Patients with Autoimmune Diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.